For research use only. Not for therapeutic Use.
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM)[1].
SSTR5 antagonist 2 (compound 10) (10 mg/kg, orally) hydrochloride increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg[1].
SSTR5 antagonist 2 hydrochloride increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors[1].
| Catalog Number | I045585 |
| CAS Number | 2988224-31-1 |
| Synonyms | 4-[8-[[3,5-diethoxy-4-(4-fluorophenyl)phenyl]methyl]-3-oxo-2,8-diazaspiro[4.5]decan-2-yl]benzoic acid;hydrochloride |
| Molecular Formula | C32H36ClFN2O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C32H35FN2O5.ClH/c1-3-39-27-17-22(18-28(40-4-2)30(27)23-5-9-25(33)10-6-23)20-34-15-13-32(14-16-34)19-29(36)35(21-32)26-11-7-24(8-12-26)31(37)38;/h5-12,17-18H,3-4,13-16,19-21H2,1-2H3,(H,37,38);1H |
| InChIKey | INOFULPPOPEZJZ-UHFFFAOYSA-N |
| SMILES | CCOC1=CC(=CC(=C1C2=CC=C(C=C2)F)OCC)CN3CCC4(CC3)CC(=O)N(C4)C5=CC=C(C=C5)C(=O)O.Cl |
| Reference | [1]. Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018;9(11):1082-1087. Published 2018 Sep 12. |
